GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Gross Margin %

AstraZeneca (AstraZeneca) Gross Margin % : 82.51% (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. AstraZeneca's Gross Profit for the three months ended in Mar. 2024 was $10,461 Mil. AstraZeneca's Revenue for the three months ended in Mar. 2024 was $12,679 Mil. Therefore, AstraZeneca's Gross Margin % for the quarter that ended in Mar. 2024 was 82.51%.


The historical rank and industry rank for AstraZeneca's Gross Margin % or its related term are showing as below:

AZN' s Gross Margin % Range Over the Past 10 Years
Min: 66.76   Med: 79.96   Max: 82.06
Current: 81.96


During the past 13 years, the highest Gross Margin % of AstraZeneca was 82.06%. The lowest was 66.76%. And the median was 79.96%.

AZN's Gross Margin % is ranked better than
93.74% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.8 vs AZN: 81.96

AstraZeneca had a gross margin of 82.51% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for AstraZeneca was -0.60% per year.


AstraZeneca Gross Margin % Historical Data

The historical data trend for AstraZeneca's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Gross Margin % Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 79.82 80.09 66.76 72.06 81.95

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.49 82.83 81.77 80.81 82.51

Competitive Comparison of AstraZeneca's Gross Margin %

For the Drug Manufacturers - General subindustry, AstraZeneca's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Gross Margin % distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Gross Margin % falls into.



AstraZeneca Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

AstraZeneca's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=37543 / 45811
=(Revenue - Cost of Goods Sold) / Revenue
=(45811 - 8268) / 45811
=81.95 %

AstraZeneca's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=10461 / 12679
=(Revenue - Cost of Goods Sold) / Revenue
=(12679 - 2218) / 12679
=82.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


AstraZeneca  (NAS:AZN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AstraZeneca had a gross margin of 82.51% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


AstraZeneca Gross Margin % Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (AstraZeneca) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (AstraZeneca) Headlines

From GuruFocus